Cargando…

Repurposed Therapeutic Agents Targeting the Ebola Virus: A Systematic Review

BACKGROUND: The Ebola virus has been responsible for numerous outbreaks since the 1970s, with the most recent outbreak taking place between 2014 and 2016 and causing an international public health emergency. Ebola virus disease (EVD) has a high mortality rate and no approved targeted treatment exist...

Descripción completa

Detalles Bibliográficos
Autores principales: Sweiti, Hussein, Ekwunife, Obinna, Jaschinski, Thomas, Lhachimi, Stefan K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522984/
https://www.ncbi.nlm.nih.gov/pubmed/28761574
http://dx.doi.org/10.1016/j.curtheres.2017.01.007
_version_ 1783252257319419904
author Sweiti, Hussein
Ekwunife, Obinna
Jaschinski, Thomas
Lhachimi, Stefan K.
author_facet Sweiti, Hussein
Ekwunife, Obinna
Jaschinski, Thomas
Lhachimi, Stefan K.
author_sort Sweiti, Hussein
collection PubMed
description BACKGROUND: The Ebola virus has been responsible for numerous outbreaks since the 1970s, with the most recent outbreak taking place between 2014 and 2016 and causing an international public health emergency. Ebola virus disease (EVD) has a high mortality rate and no approved targeted treatment exists to date. A number of established drugs are being considered as potential therapeutic agents for the treatment of EVD. OBJECTIVE: We aimed to identify potential drug repositioning candidates and to assess the scientific evidence available on their efficacy. METHODS: We conducted a systematic literature search in MEDLINE, Embase, and other relevant trial registry platforms for studies published between January 1976 and January 2017. We included drug screening, preclinical studies, and clinical studies on repurposed drugs for the treatment of EVD. The risk of bias for animal studies and nonrandomized clinical studies was assessed. The quality of reporting for case series and case reports was evaluated. Finally, we selected drugs approved by established regulatory authorities, which have positive in vitro study outcomes and at least one additional animal or clinical trial. RESULTS: We identified 3301 publications, of which 37 studies fulfilled our inclusion criteria. Studies were highly heterogeneous in terms of study type, methodology, and intervention. The risk of bias was high for 13 out of 14 animal studies. We selected 11 drugs with potential anti-EVD therapeutic effects and summarized their evidence. CONCLUSIONS: Several established drugs may have therapeutic effects on EVD, but the quality and quantity of current scientific evidence is lacking. This review highlights the need for well-designed and conducted preclinical and clinical research to establish the efficacy of potential repurposed drugs against EVD.
format Online
Article
Text
id pubmed-5522984
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-55229842017-07-31 Repurposed Therapeutic Agents Targeting the Ebola Virus: A Systematic Review Sweiti, Hussein Ekwunife, Obinna Jaschinski, Thomas Lhachimi, Stefan K. Curr Ther Res Clin Exp Article BACKGROUND: The Ebola virus has been responsible for numerous outbreaks since the 1970s, with the most recent outbreak taking place between 2014 and 2016 and causing an international public health emergency. Ebola virus disease (EVD) has a high mortality rate and no approved targeted treatment exists to date. A number of established drugs are being considered as potential therapeutic agents for the treatment of EVD. OBJECTIVE: We aimed to identify potential drug repositioning candidates and to assess the scientific evidence available on their efficacy. METHODS: We conducted a systematic literature search in MEDLINE, Embase, and other relevant trial registry platforms for studies published between January 1976 and January 2017. We included drug screening, preclinical studies, and clinical studies on repurposed drugs for the treatment of EVD. The risk of bias for animal studies and nonrandomized clinical studies was assessed. The quality of reporting for case series and case reports was evaluated. Finally, we selected drugs approved by established regulatory authorities, which have positive in vitro study outcomes and at least one additional animal or clinical trial. RESULTS: We identified 3301 publications, of which 37 studies fulfilled our inclusion criteria. Studies were highly heterogeneous in terms of study type, methodology, and intervention. The risk of bias was high for 13 out of 14 animal studies. We selected 11 drugs with potential anti-EVD therapeutic effects and summarized their evidence. CONCLUSIONS: Several established drugs may have therapeutic effects on EVD, but the quality and quantity of current scientific evidence is lacking. This review highlights the need for well-designed and conducted preclinical and clinical research to establish the efficacy of potential repurposed drugs against EVD. Elsevier 2017-02-02 /pmc/articles/PMC5522984/ /pubmed/28761574 http://dx.doi.org/10.1016/j.curtheres.2017.01.007 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Sweiti, Hussein
Ekwunife, Obinna
Jaschinski, Thomas
Lhachimi, Stefan K.
Repurposed Therapeutic Agents Targeting the Ebola Virus: A Systematic Review
title Repurposed Therapeutic Agents Targeting the Ebola Virus: A Systematic Review
title_full Repurposed Therapeutic Agents Targeting the Ebola Virus: A Systematic Review
title_fullStr Repurposed Therapeutic Agents Targeting the Ebola Virus: A Systematic Review
title_full_unstemmed Repurposed Therapeutic Agents Targeting the Ebola Virus: A Systematic Review
title_short Repurposed Therapeutic Agents Targeting the Ebola Virus: A Systematic Review
title_sort repurposed therapeutic agents targeting the ebola virus: a systematic review
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522984/
https://www.ncbi.nlm.nih.gov/pubmed/28761574
http://dx.doi.org/10.1016/j.curtheres.2017.01.007
work_keys_str_mv AT sweitihussein repurposedtherapeuticagentstargetingtheebolavirusasystematicreview
AT ekwunifeobinna repurposedtherapeuticagentstargetingtheebolavirusasystematicreview
AT jaschinskithomas repurposedtherapeuticagentstargetingtheebolavirusasystematicreview
AT lhachimistefank repurposedtherapeuticagentstargetingtheebolavirusasystematicreview